
BRAF ‐mutated malignant melanoma with chondrosarcomatous differentiation in inguinal nodal metastasis
Author(s) -
Abbati Francesca,
Altimari Annalisa,
Corti Barbara,
Dika Emi,
Sperandi Francesca,
Melotti Barbara
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3982
Subject(s) - medicine , dabrafenib , trametinib , melanoma , nodal , metastasis , metastatic melanoma , mek inhibitor , cancer research , targeted therapy , oncology , vemurafenib , cancer , mapk/erk pathway , kinase , biology , microbiology and biotechnology
We report the case of a young woman who developed metastatic melanoma in the inguinal nodal region, which acquired chondrosarcomatous differentiation and preserved the BRAF mutation found in the primary tumor. The patient was treated with a BRAF/MEK inhibitor combination therapy (dabrafenib/trametinib), which was demonstrated to be effective and well‐tolerated.